Acoustic neuroma screening: Difference between revisions
Jump to navigation
Jump to search
Simrat Sarai (talk | contribs) No edit summary |
No edit summary |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Acoustic neuroma}} | {{Acoustic neuroma}} | ||
{{CMG}}{{AE}}{{Simrat}} | {{CMG}}{{AE}}{{Simrat}} {{M.B}} | ||
==Overview== | ==Overview== | ||
According to the USPTF, screening for acoustic neuroma is not recommended. | According to the U.S. Preventive Services Task Force (USPTF), [[Screening (medicine)|screening]] for [[acoustic neuroma]] is not recommended. Evaluation for [[Neurofibromatosis type II|NF-2]] should be done in individuals with an apparently sporadic [[Acoustic neuroma|vestibular schwannoma]] occurring before the age of 30, or a [[spinal tumor]] or [[meningioma]] occurring at less than 20 years of age. | ||
==Screening== | ==Screening== | ||
According to | * According to U.S. Preventive Services Task Force (USPTF), [[Screening (medicine)|screening]] for acoustic neuroma is not recommended. | ||
* Annual hearing screening with BAER ([[Brain stem]] [[Hearing (sense)|auditory]] evoked response [[test]]), with referral to an audiologist for amplification, or speech therapy is recommended in patients with [[Neurofibromatosis type II|NF-2]]. | |||
* Evaluation for [[Neurofibromatosis type II|NF-2]] should be done in individuals with an apparently sporadic vestibular [[schwannoma]] occurring before the age of 30, or a [[spinal tumor]] or [[meningioma]] occurring at less than 20 years of age.<ref name="pmid17470137">{{cite journal| author=Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A| title=Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? | journal=Clin Genet | year= 2007 | volume= 71 | issue= 4 | pages= 354-8 | pmid=17470137 | doi=10.1111/j.1399-0004.2007.00778.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17470137 }} </ref><ref>{{Cite journal | |||
| author = [[D. Gareth R. Evans]] | |||
| title = Neurofibromatosis type 2 (NF2): a clinical and molecular review | |||
| journal = [[Orphanet journal of rare diseases]] | |||
| volume = 4 | |||
| pages = 16 | |||
| year = 2009 | |||
| month = June | |||
| doi = 10.1186/1750-1172-4-16 | |||
| pmid = 19545378 | |||
}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
| Line 11: | Line 24: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Types of cancer]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Otolaryngology]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 18:16, 24 April 2019
|
Acoustic neuroma Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Acoustic neuroma screening On the Web | |
|
American Roentgen Ray Society Images of Acoustic neuroma screening | |
|
Risk calculators and risk factors for Acoustic neuroma screening | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2] Mohsen Basiri M.D.
Overview
According to the U.S. Preventive Services Task Force (USPTF), screening for acoustic neuroma is not recommended. Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring before the age of 30, or a spinal tumor or meningioma occurring at less than 20 years of age.
Screening
- According to U.S. Preventive Services Task Force (USPTF), screening for acoustic neuroma is not recommended.
- Annual hearing screening with BAER (Brain stem auditory evoked response test), with referral to an audiologist for amplification, or speech therapy is recommended in patients with NF-2.
- Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring before the age of 30, or a spinal tumor or meningioma occurring at less than 20 years of age.[1][2]
References
- ↑ Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A (2007). "Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?". Clin Genet. 71 (4): 354–8. doi:10.1111/j.1399-0004.2007.00778.x. PMID 17470137.
- ↑ D. Gareth R. Evans (2009). "Neurofibromatosis type 2 (NF2): a clinical and molecular review". Orphanet journal of rare diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMID 19545378. Unknown parameter
|month=ignored (help)